Dialysis patients in China to benefit from a
new era in digitalized home dialysis
Fresenius Medical Care, the world's leading provider of products
and services for individuals with renal diseases, today presented
its advances in home dialysis solutions at the China International
Import Expo (CIIE) in Shanghai. The company showcased new
digitalized options that enable patients with end-stage kidney
disease to perform dialysis in the comfort of their own homes,
including the 5008S hemodialysis (HD) machine and a new automated
peritoneal dialysis (APD) machine. Importantly, these new
technologies will be backed by Fresenius Medical Care’s intelligent
DiaSmart therapy data management system (TDMS+), which enables
healthcare professionals to remotely monitor and manage patients
throughout their home dialysis treatments.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20211109006717/en/
Fresenius Medical Care unveils its
intelligent home dialysis solutions at the China International
Import Expo. (Photo: Business Wire)
Home dialysis becomes a viable treatment option for patients
in China
According to a 2012 epidemiological survey, the prevalence of
chronic kidney disease amongst adults in China is as high as
10.06%.1 People with the most advanced form of chronic kidney
disease, called end-stage kidney disease, need dialysis to sustain
their lives. Dialysis carries out most of the usual functions of
kidneys and can be given in two main ways: hemodialysis and
peritoneal dialysis. In hemodialysis or HD, an 'artificial kidney'
called a dialyzer and a HD machine are used to remove excess water
and waste products from the patient's blood. The cleaned blood is
then returned to the body. In peritoneal dialysis or PD, blood is
cleaned inside the patient's peritoneal cavity – a space within the
abdomen. PD is available as continuous ambulatory peritoneal
dialysis (CAPD) for daytime use and as automated peritoneal
dialysis (APD) for overnight use.
In China, most people who need regular dialysis have their
treatment at a hospital or dialysis center two to three times a
week. In recent years, and spurred by the COVID-19 pandemic
experience, home dialysis has increasingly become a viable
treatment option in China. Offered in the comfort of the patient's
own home, dialysis can be scheduled to suit their lifestyle –
offering greater flexibility, the ability to maintain employment
and social relationships, and to potentially improve quality of
life.2 Home-based dialysis is cost-effective, and in some remote
areas, may be the only treatment option available.
Fresenius Medical Care brings advanced home hemodialysis
solutions to China
In April 2020, the first home hemodialysis in mainland China was
successfully undertaken using Fresenius Medical Care’s 5008S home
HD machine and was reported in the specialist medical journal,
Hemodialysis International.3 The dialysis was performed
independently by the patient, confirming the feasibility of this
treatment option for patients in China.
Through the provision of the 5008S, Fresenius Medical Care is
committed to progressing home hemodialysis in China while meeting
individual patient needs. The machine offers advanced
hemodiafiltration therapy at home with features that ensure safe
and simple patient operation. The 5008S can also be operated
remotely, allowing nephrologists to monitor their patient’s therapy
in real time.
Introducing automatic peritoneal dialysis (APD) to
China
At CIIE, Fresenius Medical Care also introduced an automated
peritoneal dialysis (APD) machine to China. This computerized
dialysis option is complemented by a comprehensive service that
supports patients and healthcare professionals throughout each
stage of the treatment pathway – from creating the dialysis access
point in hospital, training the patient to perform his/her own
dialysis, monitoring the patient’s treatment data at home, and
providing ongoing follow-up.
Smart system solutions empower real-time patient
monitoring
In home dialysis, a reliable data management system is essential
to support the real-time remote monitoring of each patient’s
condition and treatment. Fresenius Medical Care’s DiaSmart system
is driven by the company’s proprietary therapy data management
system, TDMS+, and can connect remotely to both the 5008S HD and
the new APD machines. With the DiaSmart system, patient treatment
data can be uploaded in one click, allowing healthcare
professionals to monitor and manage dialysis and generate a data
analysis report. With its user-friendly interface, seamless
software-hardware connection, customized statistical analysis, and
end-to-end quality control, the TDMS+ Smart Management System helps
to standardize the operations and improve efficiency of home
dialysis.
Mr. Alan Chen, Executive Vice President of Fresenius Medical
Care Greater China, said, “This is the third time that Fresenius
Medical Care has participated at CIIE. This year, we are showcasing
our advanced smart home dialysis solutions, which are backed by the
strength of our research and development and our understanding of
healthcare professional and patient needs.”
Mr. Harry de Wit, CEO of Fresenius Medical Care Asia Pacific,
said, “With these innovations, our hope is to provide patients in
China with new options to dialyze safely in their own homes in ways
that meet their individual needs and that can enhance their quality
of life. Fresenius Medical Care will continue to commit to the
ongoing development of pioneering medical technologies and
introducing them to the renal care community and patients in China
and across Asia Pacific.”
References
- Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A.,
O'Callaghan, C. A., Lasserson, D. S., & Hobbs, F. D. (2016).
Global Prevalence of Chronic Kidney Disease - A Systematic Review
and Meta-Analysis. PloS one, 11(7), e0158765.
https://doi.org/10.1371/journal.pone.0158765
- Finkelstein, F., Schiller, B., Daoui, R., Gehr, T., Kraus, M.,
& Lea, J. et al. (2012). At-home short daily hemodialysis
improves the long-term health-related quality of life. Kidney
International, 82(5), 561-569.
https://doi.org/10.1038/ki.2012.168
- Ni, Z., Zhou, Y., Lu, R., Shen, J., Zhao, L., & Jin, H. et
al. (2021). Intelligent “Internet Plus” services in the first case
of home hemodialysis in mainland China. Hemodialysis International,
25(4). https://doi.org/10.1111/hdi.12942
ABOUT FRESENIUS MEDICAL CARE
Fresenius Medical Care is the world's leading provider of
products and services for individuals with renal diseases of which
around 3.7 million patients worldwide regularly undergo dialysis
treatment. Through its network of 4,151 dialysis clinics, Fresenius
Medical Care provides dialysis treatments for approximately 345,000
patients around the globe. Fresenius Medical Care is also the
leading provider of dialysis products such as dialysis machines or
dialyzers. Along with its core business, the Renal Care Continuum,
the company focuses on expanding in complementary areas and in the
field of critical care. Fresenius Medical Care is listed on the
Frankfurt Stock Exchange (FME) and on the New York Stock Exchange
(FMS).
For more information, please visit the company’s website:
www.freseniusmedicalcare.asia
DISCLAIMER
All information and contents of this release are for general
informational purposes only and are provided by Fresenius Medical
Care group of companies without any warranties or representations
of any kind either express or implied, including without limitation
as to their accuracy, completeness or correctness. The availability
of products or services mentioned in this release is subject to
regulatory requirements and product or service registration status
in each country, and products and technical specifications may
change without notice. Please contact one of the representatives of
Fresenius Medical Care in your country for more details. This
release may contain forward-looking statements that are subject to
various risks and uncertainties. Actual results could differ
materially from those described in these forward-looking statements
due to various factors, including, but not limited to, changes in
business, economic and competitive conditions, legal changes,
regulatory approvals, impacts related to the COVID-19 pandemic
results of clinical studies, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties
are detailed in Fresenius Medical Care AG & Co. KGaA's reports
filed with the U.S. Securities and Exchange Commission. Fresenius
Medical Care AG & Co. KGaA does not undertake any
responsibility to update the forward-looking statements in this
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211109006717/en/
Media Dr. Alexandra Villar Vice President Corporate
Communications and Branding Asia Pacific
Fresenius Medical Care 51/F Sun Hung Kai Centre, 30
Harbour Road Wanchai, Hong Kong
Alexandra.Villar@fmc-asia.com www.freseniusmedicalcare.asia
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Jul 2023 to Jul 2024